Oropharyngeal shedding of herpesviruses before and after BNT162b2 mRNA vaccination against COVID-19 |
| |
Institution: | 1. Infectious Disease Unit, Samson Assuta Ashdod University Hospital, Israel;2. Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheba, Israel;3. Microbiology Laboratory, Samson Assuta Ashdod University Hospital, Israel;4. Maccabi Healthcare Services, Israel;5. Clinical Microbiology, Sheba Medical Center, Ramat Gan, Israel |
| |
Abstract: | IntroductionConcerns were raised over an increase in Bell's palsy, herpes simplex and herpes zoster after BNT162b2 vaccination, all are manifestations of herpesviruses reactivation. As herpesviruses commonly reactivate in the oropharynx, we have hypothesized that oropharyngeal shedding of herpesviruses will increase after vaccination.MethodsImmune-competent Adults, excluding those using topical steroids or manifesting symptomatic herpesvirus infection, were sampled before BNT162b2 vaccination and one week after. Herpesviruses 1–7 shedding was tested with a multiplexed PCR.ResultsIn 103 paired samples the prevalence of herpesviruses was similar before and after vaccination: HSV1, 3.9% vs. 5.8% (p = 0.75); HSV2, 0% vs. 1% (p = not applicable, NA); VZV, 0% vs. 0% (p = NA); EBV, 14.6% vs. 17.5% (p = 0.63); CMV, 0% vs. 0% (p = NA); HHV6, 4.9% vs. 7.8% (p = 0.55); HHV7, 71.8% vs. 72.8% (p = 1); any herpesvirus, 73.8% vs. 74.8% (p = 1).DiscussionWe did not find evidence for increased oropharyngeal reactivation of herpesviruses one week after BNT162b2. |
| |
Keywords: | COVID-19 vaccine BNT162b2 Pfizer BioNTech Bell's palsy Facial palsy Herpes virus Herpes simplex virus Varicella zoster virus Epstein Barr virus Cytomegalovirus Human herpes virus 6 Human herpes virus 7 Reactivation Oropharyngeal shedding |
本文献已被 ScienceDirect 等数据库收录! |
|